THERAPEUTICS
Pharmacogenetic-guided and standard dosing did not differ for out-of-range INRs in patients initiating warfarin therapy
| The first 150 words of the full text of this article appear below. |
J L Anderson
Dr J L Anderson, Intermountain Medical Center, Murray, UT, USA; erson@intermountainmail.org
STUDY DESIGN
randomised controlled trial (RCT).
unclear allocation concealment.*
blinded (clinicians and patients).*
STUDY QUESTION
anticoagulation clinic at Intermountain Healthcare, Utah, United States.
206 patients 18–86 years of age (mean age 61 y, 53% men, based on 200 patients) in whom anticoagulation with a target international normalised ratio (INR) range of 2–3 was indicated. Exclusion criteria included pregnancy, lactation, and comorbidities precluding standard dosing (eg, advanced physiological age, serum creatinine level >2.5 mg/dl, hepatic insufficiency, and terminal disease).
warfarin initiation with pharmacogenetic-guided dosing (PGD, n = 101) or standard dosing (SD, n = 99). PGD was based on a regression equation that included genotype, age, sex, and weight and generated scores in 14 dose increments from 1–8 mg/day; twice the dose was given on the first 2 days, and subsequent dose modification was based on INR. SD was 10 mg/day
University of New Mexico, Albuquerque, New Mexico, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
